Ann Intern Med. 2016 Jun 7;164(11):715-23. doi: 10.7326/M15-1232. Epub 2016 Apr 5.
The comparative effectiveness of surgical and medical treatments on fracture risk in primary hyperparathyroidism (PHPT) is unknown.
To measure the relationship of parathyroidectomy and bisphosphonates with skeletal outcomes in patients with PHPT.
Retrospective cohort study.
An integrated health care delivery system.
All enrollees with biochemically confirmed PHPT from 1995 to 2010.
Bone mineral density (BMD) changes and fracture rate.
In 2013 patients with serial bone density examinations, total hip BMD increased transiently in women with parathyroidectomy (4.2% at <2 years) and bisphosphonates (3.6% at <2 years) and declined progressively in both women and men without these treatments (-6.6% and -7.6%, respectively, at >8 years). In 6272 patients followed for fracture, the absolute risk for hip fracture at 10 years was 20.4 events per 1000 patients who had parathyroidectomy and 85.5 events per 1000 patients treated with bisphosphonates compared with 55.9 events per 1000 patients without these treatments. The risk for any fracture at 10 years was 156.8 events per 1000 patients who had parathyroidectomy and 302.5 events per 1000 patients treated with bisphosphonates compared with 206.1 events per 1000 patients without these treatments. In analyses stratified by baseline BMD status, parathyroidectomy was associated with reduced fracture risk in both osteopenic and osteoporotic patients, whereas bisphosphonates were associated with increased fracture risk in these patients. Parathyroidectomy was associated with fracture risk reduction in patients regardless of whether they satisfied criteria from consensus guidelines for surgery.
Retrospective study design and nonrandom treatment assignment.
Parathyroidectomy was associated with reduced fracture risk, and bisphosphonate treatment was not superior to observation.
National Institute on Aging.
甲状旁腺功能亢进症(PHPT)患者手术和药物治疗对骨折风险的比较效果尚不清楚。
测量甲状旁腺切除术和双膦酸盐与 PHPT 患者骨骼结局的关系。
回顾性队列研究。
一个综合医疗服务提供系统。
1995 年至 2010 年期间所有经生化证实的 PHPT 患者。
骨密度(BMD)变化和骨折发生率。
在 2013 名接受连续骨密度检查的患者中,甲状旁腺切除术的女性(<2 年时为 4.2%)和双膦酸盐治疗的女性(<2 年时为 3.6%)的总髋部 BMD 短暂增加,而未接受这些治疗的女性和男性的 BMD 则逐渐下降(分别为>8 年时的-6.6%和-7.6%)。在 6272 名随访骨折的患者中,甲状旁腺切除术患者 10 年内髋部骨折的绝对风险为每 1000 例患者 20.4 例,双膦酸盐治疗患者为每 1000 例患者 85.5 例,而未接受这些治疗的患者为每 1000 例患者 55.9 例。甲状旁腺切除术患者 10 年内任何部位骨折的绝对风险为每 1000 例患者 156.8 例,双膦酸盐治疗患者为每 1000 例患者 302.5 例,而未接受这些治疗的患者为每 1000 例患者 206.1 例。在按基线 BMD 状态分层的分析中,甲状旁腺切除术与骨密度降低和骨质疏松患者的骨折风险降低相关,而双膦酸盐与这些患者的骨折风险增加相关。无论患者是否符合手术共识指南的标准,甲状旁腺切除术均与降低骨折风险相关。
回顾性研究设计和非随机治疗分配。
甲状旁腺切除术与降低骨折风险相关,而双膦酸盐治疗并不优于观察。
美国国家老龄化研究所。